Pfizer Announces CFO Transition

Pfizer Inc.  announced that Dave Denton, Chief Financial Officer, will step down from his current role and leave the company on August 15 for a professional opportunity outside of the pharmaceutical industry in consumer goods, which he has accepted. The company has named Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, as Interim Chief Financial Officer, effective August 16, while Pfizer conducts a comprehensive internal and external search. Dave and Cecile will work together to ensure a seamless transition.

“Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history, including Seagen, Biohaven, and Metsera, that will serve Pfizer well for years to come. We wish him the very best as he returns to the consumer goods industry,” said Albert Bourla, Chairman and Chief Executive Officer. “Given Cecile’s deep institutional knowledge and financial acumen, I have every confidence in her ability to lead Pfizer's finance organization and keep us focused on what matters most — executing our strategy and delivering for patients and shareholders."

“It has been an honor and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history,” said Dave Denton, Executive Vice President and Chief Financial Officer. “Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed and carry its important work forward."